Jubilant Therapeutics Inc.
- Home
- Companies
- Jubilant Therapeutics Inc.
- Products
- Model PD-L1 - Novel Small Molecule
Model PD-L1 - Novel Small Molecule
Strong scientific and clinical rationale for novel small molecule PD-L1 inhibitor.
Most popular related searches
T-cell
immune cell
immune checkpoints
immune surveillance
immune checkpoint
tumor microenvironment
cancer cell
tumor immunity
tumor immune
protective immunity
- PD1/PD-L1 pathway is a critical immune checkpoint in T-cell proliferation
- In the tumor microenvironment, PD-1 and PD-L1 perform a vital role in tumor progression and survival by protecting tumors from immune surveillance
- Targeting PD-1/PD-L1 pathway could reactivate cytotoxic T cells to work against cancer cells
- Anti-PD1/PD-L1 mAbs increase overall survival compared to standard of care in different tumors
- Autoimmune reactions caused by sustained activation of immune cells by mAb can potentially be overcome with a small molecule
- Low patient compliance and high cost of mAb therapies can also be overcome with a small molecule
- Potential use after initial mAb treatment as a lower-cost maintenance therapy
- Flexibility to combine with other I/O and targeted therapies
- Combination in non-oncology indications, e.g HBV where small molecule PD-1 oral modality is preferred over IV mAbs